Autonomix Medical to Present Long-Term Pain Data for Pancreatic Cancer at SSO 2026

The medical device company's minimally invasive approach aims to address chronic pain in pancreatic cancer patients.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Autonomix Medical, Inc., a medical device company focused on nerve-targeted treatments, announced that it will present new long-term clinical data on its transvascular RF energy-based approach for pain mitigation in pancreatic cancer at the Society of Surgical Oncology (SSO) 2026 Annual Meeting. The presentation, titled 'Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation,' has been accepted as an oral podium presentation.

Why it matters

Chronic pain is a major challenge for pancreatic cancer patients, and Autonomix's technology aims to provide a minimally invasive solution to improve pain control and quality of life for those facing this devastating disease. The presentation at the prestigious SSO Annual Meeting highlights the potential clinical benefits of Autonomix's approach.

The details

Autonomix's transvascular RF energy-based approach involves a catheter-based microchip sensing array that can detect and differentiate neural signals with high sensitivity. The company believes this technology can enable the diagnosis and treatment of diseases involving the peripheral nervous system. For pancreatic cancer, the goal is to use this approach to provide denervation and pain mitigation.

  • The SSO 2026 Annual Meeting will take place from March 5-7, 2026 in Phoenix, Arizona.
  • Autonomix's presentation is scheduled as an oral podium presentation.

The players

Autonomix Medical, Inc.

A medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated.

Clarke Wilkirson, PhD

Clinical Development Engineer II at Autonomix Medical, who will be delivering the presentation at the SSO 2026 Annual Meeting.

Robert Schwartz, MD

Co-Founder and Chief Medical Officer of Autonomix Medical.

Got photos? Submit your photos here. ›

What they’re saying

“Chronic pain is one of the most challenging complications faced by patients with pancreatic adenocarcinoma. We are honored to share our long-term clinical analysis at SSO 2026, demonstrating how our transvascular RF approach may provide meaningful improvements in pain control and quality of life for patients facing this devastating disease.”

— Robert Schwartz, Co-Founder and Chief Medical Officer (Autonomix Medical)

What’s next

The presentation at the SSO 2026 Annual Meeting will be an important milestone for Autonomix Medical, as it showcases the potential of their minimally invasive approach to address chronic pain in pancreatic cancer patients.

The takeaway

Autonomix Medical's innovative nerve-targeted technology holds promise to revolutionize pain management for pancreatic cancer patients, a population with significant unmet medical needs. The upcoming presentation at the prestigious SSO Annual Meeting underscores the company's commitment to advancing solutions that can improve quality of life for those facing this devastating disease.